Fatal Breakthrough COVID-19 in patients with kidney disorders

In a sample from Brazilian SIVEP-Gripe database (Sistema de Informação de Vigilância Epidemiológica da Gripe), COVID-19 breakthrough infections associated with hospitalization and death were more frequent in older patients (age ≥60 years) and those with kidney disorders.

Among 2777 patients with COVID-19 admitted to a hospital between January 5, 2021 and September 12, 2021, 257 were fully vaccinated (15 days or more after vaccine series completion), and 112 of them died. 

Vaccines have limited impact on patients with kidney failure.

As of 19th September 2021, 93% (n=5281) of patients with kidney failure requiring kidney replacement therapy (KRT) in Scotland had received two doses of an approved SARS-CoV-2 vaccine. The Glasgow study recorded 814 cases of SARS-CoV-2 infection (15.1% of the KRT population). Vaccine effectiveness against infection and hospitalization was 33% (95% CI 0-52) and 38% (95% CI 0-57) respectively. 9.2% of fully vaccinated individuals died within 28 days of a SARS-CoV-2 positive PCR test (7% dialysis patients and 10% kidney transplant recipients). This compares to <0.1% of the vaccinated Scottish population being admitted to hospital or dying due to COVID19 during that period.


REFERENCES

Estofolete CF, Fares GF, Banho CA, Sacchetto L, Campos GR, Moraes MM, Dos Santos TM, da Silva GC, Queiroz F, de Moura Mendes L, Salomão ML. Predictors of death in COVID-19 vaccine breakthrough infections in Brazil. Journal of Infection. 2022 Feb 2.

Bell S, Campbell J, Lambourg E, Watters C, O'Neill M, Almond A, Buck K, Carr E, Clark L, Cousland Z, Findlay M. The impact of vaccination on incidence and outcomes of SARS-CoV-2 infection in patients with kidney failure in Scotland. Journal of the American Society of Nephrology (Early Online Publication). 2022 Feb 2.


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis ...
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an incr...
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high ...
Read more